Artificial Intelligence for Drug Toxicity and Safety

Overview

Journal Trends Pharmacol Sci

Specialty Pharmacology

Date 2019 Aug 7

PMID 31383376

Citations 57

Authors

Anna O Basile

Alexandre Yahi

Nicholas P Tatonetti

Affiliations

Soon will be listed here.

Abstract

Interventional pharmacology is one of medicine's most potent weapons against disease. These drugs, however, can result in damaging side effects and must be closely monitored. Pharmacovigilance is the field of science that monitors, detects, and prevents adverse drug reactions (ADRs). Safety efforts begin during the development process, using in vivo and in vitro studies, continue through clinical trials, and extend to postmarketing surveillance of ADRs in real-world populations. Future toxicity and safety challenges, including increased polypharmacy and patient diversity, stress the limits of these traditional tools. Massive amounts of newly available data present an opportunity for using artificial intelligence (AI) and machine learning to improve drug safety science. Here, we explore recent advances as applied to preclinical drug safety and postmarketing surveillance with a specific focus on machine and deep learning (DL) approaches.

Citing Articles

PregMedNet: Multifaceted Maternal Medication Impacts on Neonatal Complications.

Kim Y, Maric I, Kashiwagi C, Han L, Chung P, Reiss J medRxiv. 2025; .

PMID: 39990567 PMC: 11844599. DOI: 10.1101/2025.02.13.25322242.

The TOXIN knowledge graph: supporting animal-free risk assessment of cosmetics.

Sepehri S, Heymans A, De Win D, Maushagen J, Sanctorum A, Debruyne C Database (Oxford). 2025; 2025.

PMID: 39879562 PMC: 11776536. DOI: 10.1093/database/baae121.

Role of Artificial Intelligence in Drug Discovery to Revolutionize the Pharmaceutical Industry: Resources, Methods and Applications.

Singh P, Sachan K, Khandelwal V, Singh S, Singh S Recent Pat Biotechnol. 2025; 19(1):35-52.

PMID: 39840410 DOI: 10.2174/0118722083297406240313090140.

Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-Making.

Ajmal C, Yerram S, Abishek V, Nizam V, Aglave G, Patnam J AAPS J. 2025; 27(1):22.

PMID: 39776314 DOI: 10.1208/s12248-024-01006-5.

Artificial Intelligence and Machine Learning Applications to Pharmacokinetic Modeling and Dose Prediction of Antibiotics: A Scoping Review.

Varela-Rey I, Bandin-Vilar E, Toja-Camba F, Canizo-Outeirino A, Cajade-Pascual F, Ortega-Hortas M Antibiotics (Basel). 2025; 13(12).

PMID: 39766593 PMC: 11672403. DOI: 10.3390/antibiotics13121203.

References

Tatonetti N, Ye P, Daneshjou R, Altman R . Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012; 4(125):125ra31. PMC: 3382018. DOI: 10.1126/scitranslmed.3003377. View

Agbabiaka T, Savovic J, Ernst E . Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2007; 31(1):21-37. DOI: 10.2165/00002018-200831010-00003. View

Patlewicz G, Fitzpatrick J . Current and Future Perspectives on the Development, Evaluation, and Application of in Silico Approaches for Predicting Toxicity. Chem Res Toxicol. 2015; 29(4):438-51. DOI: 10.1021/acs.chemrestox.5b00388. View

Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K . KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2016; 45(D1):D353-D361. PMC: 5210567. DOI: 10.1093/nar/gkw1092. View

Morel M, Bacry E, Gaiffas S, Guilloux A, Leroy F . ConvSCCS: convolutional self-controlled case series model for lagged adverse event detection. Biostatistics. 2019; 21(4):758-774. DOI: 10.1093/biostatistics/kxz003. View

Cocos A, Fiks A, Masino A . Deep learning for pharmacovigilance: recurrent neural network architectures for labeling adverse drug reactions in Twitter posts. J Am Med Inform Assoc. 2017; 24(4):813-821. PMC: 7651964. DOI: 10.1093/jamia/ocw180. View

Lusci A, Pollastri G, Baldi P . Deep architectures and deep learning in chemoinformatics: the prediction of aqueous solubility for drug-like molecules. J Chem Inf Model. 2013; 53(7):1563-75. PMC: 3739985. DOI: 10.1021/ci400187y. View

Kuhn M, Campillos M, Letunic I, Jensen L, Bork P . A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 2010; 6:343. PMC: 2824526. DOI: 10.1038/msb.2009.98. View

Lee K, Lee M, Kim D . Utilizing random Forest QSAR models with optimized parameters for target identification and its application to target-fishing server. BMC Bioinformatics. 2018; 18(Suppl 16):567. PMC: 5751401. DOI: 10.1186/s12859-017-1960-x. View

10.

Tannenbaum C, Day D . Age and sex in drug development and testing for adults. Pharmacol Res. 2017; 121:83-93. DOI: 10.1016/j.phrs.2017.04.027. View

11.

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S . PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2018; 47(D1):D1102-D1109. PMC: 6324075. DOI: 10.1093/nar/gky1033. View

12.

Rajkomar A, Dean J, Kohane I . Machine Learning in Medicine. N Engl J Med. 2019; 380(14):1347-1358. DOI: 10.1056/NEJMra1814259. View

13.

Ng H, Doughty S, Luo H, Ye H, Ge W, Tong W . Development and Validation of Decision Forest Model for Estrogen Receptor Binding Prediction of Chemicals Using Large Data Sets. Chem Res Toxicol. 2015; 28(12):2343-51. DOI: 10.1021/acs.chemrestox.5b00358. View

14.

Preuer K, Renz P, Unterthiner T, Hochreiter S, Klambauer G . Fréchet ChemNet Distance: A Metric for Generative Models for Molecules in Drug Discovery. J Chem Inf Model. 2018; 58(9):1736-1741. DOI: 10.1021/acs.jcim.8b00234. View

15.

Liu J, Wang G . Pharmacovigilance from social media: An improved random subspace method for identifying adverse drug events. Int J Med Inform. 2018; 117:33-43. DOI: 10.1016/j.ijmedinf.2018.06.008. View

16.

Ma J, Sheridan R, Liaw A, Dahl G, Svetnik V . Deep neural nets as a method for quantitative structure-activity relationships. J Chem Inf Model. 2015; 55(2):263-74. DOI: 10.1021/ci500747n. View

17.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

18.

Bastanlar Y, Ozuysal M . Introduction to machine learning. Methods Mol Biol. 2013; 1107:105-28. DOI: 10.1007/978-1-62703-748-8_7. View

19.

Tricco A, Zarin W, Lillie E, Jeblee S, Warren R, Khan P . Utility of social media and crowd-intelligence data for pharmacovigilance: a scoping review. BMC Med Inform Decis Mak. 2018; 18(1):38. PMC: 6001022. DOI: 10.1186/s12911-018-0621-y. View

20.

Comfort S, Perera S, Hudson Z, Dorrell D, Meireis S, Nagarajan M . Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media. Drug Saf. 2018; 41(6):579-590. PMC: 5966485. DOI: 10.1007/s40264-018-0641-7. View